Waseem Albasha
Critical Care Medicine · Sun City West, AZNPI 1659720217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $850, 7.5 times the $114 reported in 2020.
Across 61 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$352
- Boehringer Ingelheim$197
- Pulmonx Corporation$166
- Insmed, Inc.$137
- Abiomed$119
- Viatris Specialty LLC$106
- plus $673 from 16 others
What the payments were for
- Food & beverage$1,62893%
- Education$1227%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $352 |
| Boehringer Ingelheim | 6 | $197 |
| Pulmonx Corporation | 6 | $166 |
| Insmed, Inc. | 7 | $137 |
| Abiomed | 1 | $119 |
| Viatris Specialty LLC | 4 | $106 |
| Baxter Healthcare | 5 | $96 |
| Mylan Specialty L.p. | 3 | $72 |
| Sanofi | 3 | $62 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Olympus Corporation Of The Americas | 2 | $55 |
| Olympus America Inc. | 1 | $55 |
| GSK | 3 | $47 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Vifor Pharma, Inc. | 1 | $30 |
| Inogen, Inc. | 1 | $27 |
| Merck | 1 | $27 |
| Philips North America LLC | 1 | $26 |
| ZOLL Respicardia, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$125
How this compares
$1,750 in reported general payments places this provider in the 75th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $36,337 |
| Spiriva RespimatTiotropium Bromide | 19 | $16,255 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,969 |
| Spiriva HandihalerTiotropium Bromide | 24 | $14,055 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,689 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $7,917 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $6,885 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $4,789 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $3,578 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,137 |
| Fluconazole | 12 | $2,410 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,857 |
| Fluticasone Propionate | 40 | $649 |
| Montelukast Sodium | 24 | $226 |
| Azelastine Hcl | 14 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $47 | $36,33755 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $197 | $24,94433 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $352 | $22,88649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Sun City West
- Carlos Alvarado-ValdesSun City West$4K
- Joon KimSun City West$950
- Naomi HabibPhoenix$298K
- Heather PrzybylPhoenix$126K
- Douglas MapelPrescott$125K
- Akshay MuralidharScottsdale$44K
- Syed ShahryarPhoenix$20K
- Rodrigo Cartin-CebaScottsdale$18K
- Robert MathenyKingman$10K
- Reena BansalScottsdale$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.